Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387287 | 1.00 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP2C9CYP2C19TP53 | |
| SCHEMBL26969782 | 0.89 | NOTUM (0.41) | CYP3A4CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL25238614 | 0.88 | NOTUM (0.42) | CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29387124 | 0.84 | HTR6 (0.40) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL25232753 | 0.84 | HTR6 (0.40) | CYP3A4CYP2D6CYP2C9CYP2C19MEN1 | |
| SCHEMBL26969745 | 0.82 | HDAC1 (0.41) | — | |
| SCHEMBL26969707 | 0.81 | TSHR (0.38) | CYP3A4CYP2D6CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL29703821 | 0.81 | NR1H3 (0.43) | CYP3A4CYP2D6CYP2C9CYP2C19TP53 | |
| SCHEMBL25279584 | 0.78 | ACLY (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19HTT | |
| SCHEMBL26969779 | 0.78 | NOTUM (0.40) | CYP3A4CYP2D6CYP2C9CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4192957-A2 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CYP3A4 2481/4885CYP2D6 2369/4885CYP2C9 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.